Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial

Monday, July 15, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses a phase 2 trial named TORREY, which evaluates Seralutinib in adults suffering from pulmonary arterial hypertension (PAH). This trial is designed as a randomized, double-blind, placebo-controlled study, ensuring a high level of scientific rigor. The focus on PAH highlights the need for effective treatments in this area.
Price reaction · baseline $1.185 (2024-07-15T19:05:00.000Z) · hit during market hours · clean, no other GOSS news in the window
day 0 close · peak
-0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • The trial is a randomized, double-blind, placebo-controlled study, indicating rigorous methodology.
  • Seralutinib is being investigated for pulmonary arterial hypertension, a significant health concern.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the TORREY trial about?

The TORREY trial investigates Seralutinib in adults with pulmonary arterial hypertension.

What type of study is the TORREY trial?

It is a randomized, double-blind, placebo-controlled phase 2 trial.

What condition is Seralutinib targeting?

Seralutinib is targeting pulmonary arterial hypertension (PAH).

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary arterial hypertension phase 2 trial clinical trial
Last updated: Jul 15, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →